

12 May 2025

Osteopore elevates partnership with Kelyniam for the U.S. craniofacial market

Highlights

- Osteopore strikes non-exclusive 3-year distribution agreement with Kelyniam Global, Inc. (Kelyniam) for its craniofacial implants in the U.S.
- Kelyniam is a publicly traded (OTC:KLYG) medical device company specialising in custom cranial and craniofacial implants that showed strong profitability in 2024.
- Osteopore expects the first purchase to follow promptly after the agreement is signed.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Company has secured a non-exclusive 3-year distribution arrangement with Kelyniam Global, Inc (Kelyniam), a publicly traded medical device company (OTC:KLYG), to market its craniofacial implants in the U.S.

Kelyniam is an innovative medical device manufacturing company that specialises in the production of custom cranial and craniofacial PEEK implants. As an industry leader, Kelyniam is the only cranial and craniofacial implant company with a patented integrated fixation system, and that can produce an implant within 24-48 hours for rush and expedited cases. Kelyniam processes are supported by 3D printing, along with advanced design software and CAD/CAM manufacturing capabilities to ensure the highest level of precision is achieved.



Kelyniam is poised for growth and announced record revenue in 2024¹, with revenues increasing 24.6% year-on-year from US\$2.7M in 2023 to US\$3.3M in 2024, while net operating income was US\$277k in 2024 compared to a net operating income loss of US\$239k in 2023.

This augmented partnership with Kelyniam is expected to result in stronger U.S. customer service and support, along with higher precision in securing product listing in hospitals and exposure to industry leading surgeons, both of which are key elements in the product adoption process. Previously, Kelyniam was appointed as a sub-distributor under Bioplate Inc².

With an addressable market of US\$1.1 billion³ (Compound Annual Growth Rate (CAGR) of 6.4% from 2022 to 2030⁴), the U.S. cranial implant market is a significant opportunity for Osteopore.

Commenting on the partnership with Kelyniam, CEO Dr Yujing Lim, said:

“The U.S. market is a significant market opportunity for Osteopore, and we recognise that changes are necessary to reinvigorate the business.

“Kelyniam has demonstrated its ability to manufacture and distribute effectively, as shown by their record performance in 2024. We believe that working directly with Kelyniam allows us to leverage their established access to hospitals and potential customers, thereby accelerating customer access to Osteopore’s products.

“We have given careful consideration to the pricing structure to ensure sustainability and are encouraged by Kelyniam’s enthusiasm towards our products and its potential in the U.S., even with the current instability in U.S. foreign trade policy” said Dr Lim.

¹ <https://www.otcmarkets.com/stock/KLYG/news/KELYNIAM-ACHIEVES-RECORD-REVENUE--PROFITABILITY-FOR-2024?id=470612>

² ASX Announcement, OSX Strengthens Presence in the Eastern Region of the USA, 11 Apr 2023.

³ CETAS Healthcare commissioned market research report, December 2020.

⁴ <https://www.globenewswire.com/news-release/2023/02/23/2614470/0/en/Cranial-Implants-Market-Size-Growing-at-6-4-CAGR-Set-to-Reach-USD-2-058-Million-By-2030.html>



Commenting on the partnership with Osteopore, Kelyniam Chief Operating and Revenue Officer Miss Desiree Webb, said:

"Innovation and alignment with organizations that share our passion for regenerative options in the cranial and craniofacial space are imperative to the success of Kelyniam. Osteopore is an exceptional addition for surgeons in need of a biomimetic and bioresorbable option for areas where natural, healthy bone growth is desired.

"Osteopore will complement Kelyniam's culture of providing a high level of service and expertise for the most complex cases by leveraging key opinion leaders in various surgical specialties.

"In support of providing the best options for patients requiring cranial or craniofacial surgery, we are honoured to represent Osteopore in the United States, and look forward to making great strides" said Miss Webb.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations
Purple
E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.



Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

